Tracking the cellular targets of platinum anticancer drugs: Current tools and emergent methods

[Display omitted] •Overview of methods to identify nucleic acid targets of Pt(II).•Utility and development of pre- and post-treatment tethered fluorescent Pt(II).•Enrichment strategies for identification of Pt(II)-proteins. Since its FDA approval just over 40 years ago, cisplatin and its more recent...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Inorganica Chimica Acta 2019-12, Vol.498, p.118984, Article 118984
Hauptverfasser: Sutton, Emily C., McDevitt, Christine E., Yglesias, Matthew V., Cunningham, Rachael M., DeRose, Victoria J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] •Overview of methods to identify nucleic acid targets of Pt(II).•Utility and development of pre- and post-treatment tethered fluorescent Pt(II).•Enrichment strategies for identification of Pt(II)-proteins. Since its FDA approval just over 40 years ago, cisplatin and its more recently approved analogues, carboplatin and oxaliplatin, have been widely used to treat a spectrum of different cancers worldwide. Despite the overall success of this class of anticancer agents, identification of their precise cellular targets is still an area of intense study due to the side effects and resistance profiles of these drugs. As these compounds are small molecules with low specificity, target identification in the context of a complex cellular environment presents a significant challenge. In this review, we summarize established methods to identify RNA, DNA, and protein targets of platinum compounds. We also review recent additions to the library of fluorescent-Pt derivatives as well as click-enabled platinum compounds that can be used for post-treatment labeling.
ISSN:0020-1693
1873-3255
DOI:10.1016/j.ica.2019.118984